Monoclonal Antibodies in Breast and Ovarian Cancer
Author Information
Author(s): R.C.F. Leonard, J. Fisken, J.E. Roulston
Primary Institution: ICRF Medical Oncology Unit, Western General Hospital
Conclusion
The conference highlighted the potential of monoclonal antibodies and various screening methods in improving the management of breast and ovarian cancer.
Supporting Evidence
- Ovarian cancer has a high mortality rate and is a major health problem.
- Screening for ovarian cancer could potentially save lives, especially for those with a family history.
- Breast cancer screening may not benefit all patients due to lead time bias.
- Markers like CA125 are important for monitoring ovarian cancer but require further validation.
Takeaway
Doctors are trying to find better ways to detect and treat breast and ovarian cancer using special proteins called monoclonal antibodies.
Methodology
The workshop included presentations and discussions on screening, management, and imaging techniques related to breast and ovarian cancer.
Potential Biases
Potential bias in patient population selection and the need for careful validation of methodologies were discussed.
Limitations
The need for large randomized population studies and the variability in tumor marker assays were noted as limitations.
Want to read the original?
Access the complete publication on the publisher's website